Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ciba Rescula For Glaucoma Will Have DTC Print Ads At September Launch

Executive Summary

Novartis subsidiary Ciba Vision is preparing direct-to-consumer print ads for a Sept. 18 launch of its second-line glaucoma therapy Rescula.

You may also be interested in...

Novartis Rx Exec Changes Include U.S. COO Epstein To Oncology Unit Head

Novartis Pharmaceutical U.S. Chief Operating Officer David Epstein will head the Swiss company's new global oncology business unit effective Sept. 1.

Pharmacia Xalcom

Xalatan (latanoprost) and timolol (Merck's Timoptic and generics) combination product deemed "approvable" June 2 for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta blockers. The application was submitted during the fourth quarter of 1999 and is under priority review. Pharmacia currently markets Xalatan for open-angle glaucoma and ocular hypertension

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts